Sustained cytokine delivery for anticancer vaccination: liposomes as alternative for gene-transfected tumor cells.
Vaccination with tumor cells genetically engineered to produce interleukin (IL)-2 is an attractive strategy to enhance antitumor immune responses. The improved antitumor immunity upon vaccination with IL-2 gene-modified tumor cells may be due to the prolonged presence of the cytokine at the vaccination site. Because liposomes have been used for sustained delivery of a variety of agents, we compared the protective effect of vaccines consisting of IL-2 gene-modified B16 melanoma cells to that of vaccines composed of IL-2 liposomes and irradiated melanoma cells. The results indicate that both approaches equally protect against a lethal challenge with B16 melanoma cells. More than 20% of the protected animals developed vitiligo at the vaccination and/or tumor challenge site.
Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, The Netherlands.
F J
FJ
Koppenhagen
Z
Z
Küpcü
G
G
Wallner
D J
DJ
Crommelin
E
E
Wagner
G
G
Storm
R
R
Kircheis
D000818:Animals; D019496:Cancer Vaccines / Q000008:administration & dosage*; D005260:Female; D007113:Immunity, Innate; D007376:Interleukin-2 / Q000008:administration & dosage* / Q000235:genetics / Q000276:immunology; D008081:Liposomes; D008546:Melanoma, Experimental / Q000235:genetics* / Q000276:immunology* / Q000517:prevention & control; D051379:Mice; D008810:Mice, Inbred C57BL; D014162:Transfection
D019496:Cancer Vaccines; D007376:Interleukin-2; D008081:Liposomes